Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough Acquires Phase II HBV Agent In $110 Mil. Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Compound utilizes Metabasis' HepDirect technology to enable higher concentrations of the drug in the liver, and lower concentrations elsewhere, Schering says.

You may also be interested in...



Metabasis Reports Disappointments On Two Pipeline Candidates

Phase IIb trial of a type 2 diabetes candidate fails to show efficacy over metformin, and Schering-Plough also returns rights to hepatitis b candidate pradefovir.

Metabasis Reports Disappointments On Two Pipeline Candidates

Phase IIb trial of a type 2 diabetes candidate fails to show efficacy over metformin, and Schering-Plough also returns rights to hepatitis b candidate pradefovir.

Dynavax To Seek Experienced Vaccines Partner To Commercialize Heplisav

The company reports positive Phase III data for the hepatitis B vaccine showing 98.5% seroprotection after two doses.

Topics

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel